SECTIONS
SUBSCRIBE
Managed Care

Search form

  • News
  • Politics & policy
  • Drug management
  • Payers
  • Providers
  • Current Issue
  • More
    • Past issues
    • Value-Based Care
    • Profiles
    • Conversations
    • Tomorrow's Medicine
    • Original research
    • Pharm D Corner
    • Viewpoints
    • Legislation & regulation
    • Contact Us

Most Popular

CMS Puts Off Decision on Lowering Drug Prices Patients Pay at the Pharmacy

The Centers for Medicare and Medicaid Services (CMS) has laid out a bevy of initiatives that officials said would reduce drug prices for patients covered by the Medicare Part D prescription drug program—but they have made no decisions yet on an issue that has confounded lawmakers and patients alike,…
Read more

New Research Finds No Link Between Hormonal Birth Control and Depression

Women face several options when it comes to birth control, so potential side effects often factor into their decision. Depression is a common concern for many women, but a new study by researchers at The Ohio State University (OSU) Wexner Medical Center is putting patients at ease. It found there’s…
Read more

HTX-011 Provided Postoperative Pain Relief, Reduced Need for Opioids in Phase 3 Trials

Positive topline results have been reported from the completed phase 3 studies of the investigational agent HTX-011 (Heron Therapeutics) in patients undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2). HTX-011 achieved all primary and key secondary endpoints in both phase…
Read more

FDA Green-Lights First Fully Interoperable Continuous Glucose Monitoring System 

The FDA has permitted marketing of the Dexcom G6 (Dexcom, Inc.) integrated continuous glucose monitoring (iCGM) system for determining blood glucose levels in patients two years of age and older with diabetes. This is the first type of continuous glucose monitoring system permitted by the agency to…
Read more

Taking On Too Much

This issue of Managed Care was billed as being about Medicaid managed care and vulnerable populations. But as grumpy editors often say, that’s a topic not a story. And it didn’t take us very long to discover that the story was social determinants of health. Lola Butcher, a regular contributor to…
Read more

New Test for Diagnosing Insulin Resistance Could Turn the Tide Against Diabetes

This article marks a milestone. My first Tomorrow’s Medicine column ran in the April 2003 issue of Managed Care. As I thought about what to write about for this column, I reflected back on the past 15 years. Since the beginning, Tomorrow’s Medicine has focused on cutting-edge, highly technical,…
Read more

Duobrii Produces Positive Phase 3 Results in Psoriasis Treatment

Positive first-time results have been published for Duobrii (halobetasol propionate and tazarotene lotion, Ortho Dermatologics) for the treatment of plaque psoriasis. The data appear in the Journal of the American Academy of Dermatology. Two phase 3, multicenter, randomized, double-blind clinical trials…
Read more

Keytruda Scores Another Win in Phase 3 Lung Cancer Study

The pivotal, phase 3 KEYNOTE-042 trial evaluating pembrolizumab (Keytruda), Merck’s anti-programmed death-1 (PD-1) therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non–small-cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary…
Read more

FDA Restricts Sale and Distribution of Essure Contraception Device

The FDA has issued an order to restrict the sale and distribution of the Essure permanent contraception device (Bayer) to ensure that all women considering use of the device are provided with adequate risk information so that they can make informed decisions. The agency is taking this step after becoming…
Read more

Researchers Propose New Alzheimer’s Definition Based on Biology

Alzheimer’s researchers have proposed a radical change in the way the disease is defined, focusing on biological changes in the body rather than clinical symptoms such as memory loss and cognitive decline, according to a Reuters report. The new research framework, released by the Alzheimer’s Association…
Read more

Opioid Overdoses In Children Soar

The number of children ages 1 to 17 admitted to hospitals for an overdose of opioids nearly doubled from 797 patients between 2004 and 2007 and 1,504 between 2012 and 2015. The oldest children in the study in Pediatrics, those between 12 and 17, accounted for over 60% of patients admitted for opioid overdose.

Read more

FDA OKs Second Ovarian Cancer Indication for PARP Inhibitor Rubraca 

The FDA has approved rucaparib (Rubraca, Clovis Oncology, Inc.) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The agency granted regular approval…
Read more

Briefly Noted April 2018

The window of time between a stroke and effective thrombectomy may be as long as 16 hours in many cases, according to a study in the New England Journal of Medicine. But advanced brain imaging technology may give physicians an extra 10 hours or more to respond to treat some strokes. A study published…
Read more

Managed care rules in Medicaid

Thirty-nine states had contracts with comprehensive risk-based Medicaid managed care organizations and in 29 of those states, 75% or more of the Medicaid beneficiaries were enrolled in one of those organizations. A large majority (27 of 32) of the Medicaid expansion states used managed care organizations to cover newly eligibly adults.

Read more

FDA Approves Opdivo Plus Yervoy Combination for Certain Renal Cell Carcinoma

The FDA has granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb) in combination for the treatment of intermediate- or poor-risk, previously untreated advanced renal cell carcinoma (RCC). The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label…
Read more

Pages

  • « first
  • ‹ previous
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • next ›
  • last »
Facebook Twitter LinkedIn RSS Feed
  • Contact Us
  • Our History
  • Terms & Conditions of Use Agreement
  • Address and Subscription Changes
  • 2018 Editorial Calendar
  • 2018 Space and Material Due Dates
  • BPA Statement
  • Submitting Original Research
  • Submitting Viewpoints
  • Site Map
  • Contact Webmaster
  • P&T Community
© 2018 MediMedia, an ICON plc company. All rights reserved.